Substance / Medication

Pilocarpine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

57 trials linked to this intervention

57
Total Trials
26
Recruiting
7
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance.
Waring George O, Brujic Mile, McGee Selina et al. · Clin Exp Optom · 2024
PMID: 38044272RCT
Effect of Pilocarpine Hydrochloride on the Schlemm Canal in Healthy Eyes and Eyes With Open-Angle Glaucoma.
Skaat Alon, Rosman Michael S, Chien Jason L et al. · JAMA Ophthalmol · 2016
PMID: 27347646RCT
In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride.
Miyazaki S, Suzuki S, Kawasaki N et al. · Int J Pharm · 2001
PMID: 11604255Observational
RHEGMATOGENOUS RETINAL DETACHMENT AFTER INITIATION OF PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION 1.25% FOR TREATMENT OF PRESBYOPIA.
Eton Emily A, Zhao Peter Y, Johnson Mark W et al. · Retin Cases Brief Rep · 2024
PMID: 35963010Case Report
A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride.
Fujii Teruhiro, Kawasoe Kentaro, Nishizawa Yuki et al. · CEN Case Rep · 2019
PMID: 31077057Case ReportFull text (PMC)
Eye drops preservative as the cause of corneal band keratopathy in long-term pilocarpine hydrochloride treatment.
Pavicić-Astalos Jasna, Lacmanović-Loncar Valentina, Petric-Vicković Ivanka et al. · Acta Clin Croat · 2012
PMID: 22920012Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pilocarpine hydrochloride (substance)
SNOMED CT
387035001
UMLS CUI
C0770456

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
57
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.